283
Views
21
CrossRef citations to date
0
Altmetric
Review

Treatment planning for children with attention-deficit/hyperactivity disorder: treatment utilization and family preferences

&
Pages 45-56 | Published online: 17 Jan 2011

Abstract

Background

Attention-deficit/hyperactivity disorder (ADHD) is a common condition that often results in child and family functional impairments. Although there are evidence-based treatment modalities available, implementation of and persistence with treatment plans vary with patients. Family preferences also vary and may contribute to variability in treatment utilization.

Objective

The objective of this study is to describe the evidence-based treatments available for ADHD, identify patterns of use for each modality, and examine patient and parent treatment preferences.

Method

Literature review.

Results

Treatment options differ on benefits and risks/costs. Therefore, treatment decisions are preference sensitive and depend on how an informed patient/parent values the tradeoffs between options. Literature on patient and parent ADHD treatment preferences is based on quantitative research assessing the construct of treatment acceptability and qualitative and quantitative research that assesses preferences from a broader perspective. After a child is diagnosed with ADHD, a variety of factors influence the initial selection of treatment modalities that are utilized. Initial parent and child preferences are shaped by their beliefs about the nature of the child’s problems and by information (and misinformation) received from a variety of sources, including social networks, the media, and health care providers. Subsequently, preferences become further informed by personal experience with various treatment modalities. Over time, treatment plans are revisited and revised as families work with their health care team to establish a treatment plan that helps their child achieve goals while minimizing harms and costs.

Conclusions

Studies have not been able to determine the extent to which utilization rates are consistent with the underlying distribution of informed patient/parent treatment preferences. There are challenges to ensure that patient/parent preferences are consistently well informed, elicited, and discussed in the treatment planning process. Interventions are needed to promote such interactions.

Introduction

Attention-deficit/hyperactivity disorder (ADHD) is a neurobehavioral condition that often results in academic, social, and family functional impairments. ADHD is prevalent, as 8.7% of children aged 8–15 years in the US meet diagnostic criteria for ADHD.Citation1 Fortunately, there are evidence-based treatment modalities available. However, implementation of and persistence with treatment plans vary with patients. Family preferences contribute to variability in treatment implementation and adherence to treatment. Further, familial preferences appear to vary across treatment modalities. The purpose of this review is to describe the evidence-based treatments available for ADHD, identify patterns of use for each modality, and examine patient and parent treatment preferences. This synthesis of information will hopefully inform future research in order to better understand the relationship between preferences and treatment utilization as well as interventions to improve treatment planning for children with ADHD.

Study identification

Studies included in this review were found in the MedLine and PsychInfo databases by crossing the terms “attention deficit hyperactivity disorder”, “attention deficit disorder”, and “ADHD” with key terms, including “preferences”, “adherence”, “treatment”, “management”, “guideline”, “primary care”, and “communication”. Among included articles, a secondary review of cited references was performed.

Evidence-based ADHD treatment options

The Multimodal Treatment Study of Children with ADHD (MTA)Citation2 provides evidence to support the use of 1) psychosocial treatments alone, 2) medication alone, or 3) combined treatment (eg, both psychosocial and medication treatments). In this review we describe each treatment modality; provide an estimate for the likelihood of benefit; identify possible shortcomings, including possible harms, costs, and barriers to implementation; and provide estimates for the use of and persistence with each modality. We limit our discussion to treatment modalities employed in the MTA study because these are the only modalities endorsed in prominent ADHD treatment guidelines.Citation3,Citation4 Although additional treatment modalities are increasingly being usedCitation5Citation7 and tested,Citation8 none is endorsed in the current treatment guidelines.Citation3,Citation4

Psychosocial treatments

Psychosocial approaches to treatment can cover a range of specific interventions, but most of the existing evidence-based interventions support two primary components: direct contingency management and clinical behavior therapy. Direct contingency management focuses on direct control of consequences for target behavior. Clinical behavior therapy involves teaching parents and/or teachers to implement strategies for managing ADHD in everyday settings. The MTA study included both components of psychosocial intervention as part of its psychosocial treatment strategy. Families participated in parent training groups, a school-based intervention, and a summer treatment program.Citation2 The parent training groups involved 27 group (six families/group) and eight individual sessions. Training focused on teaching parents strategies (eg, giving effective commands, setting gradual goals, and using reward systems) to encourage desired behaviors and eliminate problem behaviors. The school-based intervention involved teachers learning classroom behavior management strategies during 10–16 training sessions and paraprofessional aides working one on one with children for half the school day for up to 60 days to improve classroom behaviors. A teacher-completed daily report card was used to communicate child performance to parents, who reinforced behavior with home-based rewards. Finally, children attended a summer treatment program 9 h a day, 5 days/week, for 8 weeks. Summer treatment program psychosocial interventions were group based and delivered in recreational and classroom settings to improve social skills and classroom behaviors.

At the end of the 14-month MTA study, 34% of children who received these intensive psychosocial treatments (without any medication) improved to the point of ADHD symptom remission (ie, they were no more inattentive, hyperactive, or impulsive than the average child their age without ADHD).Citation9 No child or parent in the MTA study reported harm from the psychosocial interventions. However, there are potential shortcomings from these treatments. Obviously, parents and children need to invest time and effort into developing new skills for these approaches to be successful. In addition, there is an out-of-pocket cost to families interested in receiving these interventions in clinical settings. Moreover, the availability of interventions similar to those employed in the MTA study may be limited or nonexistent in some areas. Psychosocial treatments that are available likely vary in intensity and their adherence to evidence-based intervention programs.

In the MTA study, the parents of only 1 of 289 children randomly assigned to receive psychosocial treatment (in psychosocial treatment alone and combined treatment groups) refused to initiate psychosocial treatment.Citation2 Of those who participated in the intervention, attendance at treatment sessions was high. Families attended an average of 77.8% of parent training sessions and 91% of possible summer treatment program days.Citation2 However, the MTA study did not measure whether parents actually implemented psychosocial treatments as intended. Although parents who failed to attend sessions could not learn the parenting skills taught, being present at sessions did not ensure that parents either learned or implemented the parenting skills taught.Citation10 Efforts to disseminate parent training sessions in community settings highlight potential challenges related to session attendance. Barkley et alCitation11 offered manualized and well-validated parent training groups (10 sessions followed by 4 booster sessions) to parents of disruptive preschool age children. Thirty-three percent of parents did not attend any session, 25% of parents attended 1–4 sessions, 29% attended 5–8 sessions, and 13% attended 9–14 sessions.Citation11 The authors speculate that poor attendance contributed to the intervention’s lack of benefit. Despite its potential importance as a mediator of treatment outcome, attendance is under-reported in studies of psychosocial treatment among parents of children with ADHD.Citation10 In addition, there are few estimates of utilization of psychosocial treatments. Among children with ADHD in North Florida, USA, in 1995, 25% received multimodal treatment that included psychosocial treatments.Citation12 We are not aware of any such estimates among a nationally representative sample.

Medication

The most widely evaluated approach to treating ADHD has been the use of different types of medications, particularly stimulant medications. The MTA medication algorithm started with a 28-day, double-blind, daily-switch titration of methylphenidate hydrochloride at a range of dosages to determine the best starting dosage.Citation13 Similar to previous research, 77% of children in the MTA group had a positive response to methylphenidate.Citation14 Among those children who did not, about half had a positive response to a trial of dextroamphetamine.Citation14 Subsequently, children had monthly visits with a pharmacotherapist to monitor benefit and side effects and adjust dosage and/or medication to optimize response. Adjustment decisions were based on information obtained from children, parents, and teachers on a monthly basis. By the end of 14 months of medication treatment, only 29% of children remained on the original medication dosage.Citation15 The average number of adjustments was two per child.Citation15

Fifty-six percent of children who received the MTA medication algorithm (without any psychosocial treatment) improved to the point of ADHD symptom remission by the end of the 14-month study.Citation9 Side effects from medication were common, with 50% of children reporting mild, 11% moderate, and 3% severe side effects at some time during the 14 months of treatment.Citation2 In clinical settings, families often incur an out-of-pocket cost to obtain medication. In addition, medication management obtained in primary care settings likely differs from MTA procedures with regard to initial titration (eg, open-label upward titration rather than a blinded, placebo-controlled trial) and frequency of monitoring after the child is stable (eg, every 3–6 months rather than monthly).Citation3 In addition, there are often logistical barriers to obtaining feedback from teachers to inform medication management decisions.Citation16

In the MTA study, the parents of 18 of 289 children (6.2%) randomly assigned to receive medication (in medication alone and combined treatment groups) refused to initiate medication, and an additional 20 parents (6.9%) discontinued medication some time after their child’s initial titration was complete.Citation2 Despite coordinated research efforts to optimize adherence (eg, pill counts, intermittent saliva measurement to monitor methylphenidate taking, and encouragement of families to reschedule missed visits),Citation2 medication use varied considerably among children in the MTA study. Just over half of children (136/254 = 53.5%) had detectable levels of methylphenidate every time a readable saliva measurement was obtained during the 14-month study.Citation17 Medication adherence was a significant mediator of symptom reduction in the MTA study.Citation13 Since the MTA study was published in 1999 there have been few estimates of ADHD medication use in community-based clinical samples. One such study, which included a sample representative of the US population in 2000–2002, reported that Caucasian children were more than twice as likely to have received treatment for ADHD (5.8%) than African-American (2.8%) or Hispanic (2.4%) children.Citation18 Another study employed a sample representative of the US population in 2003 and found that only 56.3% of children with reported ADHD diagnosis were being treated with medication at the time of the survey.Citation19 Medication treatment rates for children diagnosed with ADHD varied widely by state, with a range from 40.6% in California to 68.5% in Nebraska.Citation19 Analysis of California Medicaid claims (2000–2003) demonstrated that 30% of children experience a 30-day gap in ADHD medication supply after receiving their initial prescription.Citation20 The average time from initiation of ADHD medication to experiencing a 30-day gap in treatment was <150 days.Citation20 Less than half of these children resumed ADHD treatment within 90 days after experiencing a gap in medication supply.Citation20 Among Medicaid recipients in CaliforniaCitation20 and Texas,Citation21 use of extended-release ADHD medications, compared with immediate-release medications, predicted greater persistence with medication. In a study of children with ADHD cared for in Kaiser Permanente of Northern California, a nonprofit integrated health care delivery system, medication copayment amount was found to be inversely related to duration of medication treatment (ie, lower out-of-pocket expense for filling a prescription related to longer persistence with medication treatment).Citation22 The current literature on changes in ADHD medication use over time is limited by reliance on large pharmacy and/ or claims databases that lack linkage to the child’s clinical treatment plan. Thus, it is impossible to know the proportion of children who discontinue medication use because they are able to achieve their goals for treatment without medication versus those who continue to struggle and discontinue medication for other reasons.

Combined treatment

Combined treatment involves receipt of both the psychosocial and medication treatments described above. At the end of the 14-month MTA study, 68% of children who received combined treatment improved to the point of symptom remission.Citation9 In addition, children who received combined treatment ended the 14-month study on a lower dose (18% less medication per day) than those in the medication only group.Citation15 This is noteworthy because side effects, when present, can become more severe as dosages increase.Citation14 The shortcomings of each modality involved in combined treatment are listed in this review within the description of each treatment option. The cumulative effect of shortcomings, such as out-of-pocket cost, may weigh significantly in the treatment planning process for families with limited resources. Utilization of these modalities is described previously.

ADHD treatment planning: a series of preference-sensitive decisions

The MTA study demonstrated the comparative efficacy of psychosocial treatment alone, medication treatment alone, and combined treatment. As reviewed previously, the chance of symptom remission and potential shortcomings (eg, harms and costs) vary across these treatment conditions. As a result, ADHD treatment guidelines recognize all three options as medically reasonable.Citation3,Citation4 These guidelines stress the importance of taking into account family goals, preferences, cultural values, and concerns when developing a treatment plan.Citation3,Citation4 The best initial treatment choice for the individual child depends on how an informed patient and parent(s) value the benefits relative to the potential harms/costs, as well as their ability to implement each option. Such decisions have been described as preference sensitive.Citation23 As families accrue experience with one or more treatment modalities and recognize the actual benefits and harms/cost experienced by their child, the best treatment plan becomes one that strikes an acceptable balance between enabling progress toward current and future child/family goals while minimizing any harms/costs.

Patient and caregiver preferences

Our current understanding of patient and parent ADHD treatment preferences is based on quantitative research that assesses the construct of treatment acceptability and qualitative and quantitative research that assesses preferences from a broader perspective. Each method contributes to the literature on what matters most to patients and parents when selecting ADHD treatments. In this review we highlight the key findings, limitations, and unanswered questions.

Treatment acceptability

Studies of treatment acceptability among parents of children with ADHD are reviewed here. These studies have employed a variety of measures: 1) Treatment Evaluation Inventory (TEI),Citation24Citation26 2) Modified TEI,Citation27 3) Adapted TEI Short Form,Citation28 4) Treatment Acceptability Questionnaire (TAQ),Citation29 5) ADHD Knowledge and Opinion Scale (AKOS),Citation30 6) Modified AKOS,Citation31 and 7) AKOS-Revised (AKOS-R).Citation32 The commonalities and differences between these scales with regard to the measurement of the “acceptability” construct are summarized in . All scales ask respondents to rate their agreement with a series of statements, and all generate a total score, with higher scores indicating greater acceptability. Unlike versions of the TEI and TAQ, which have a single scale that can be completed in reference to various treatment options/modalities, versions of the AKOS have separate scales that are specific for medication acceptability, psychosocial treatment acceptability, and psychosocial treatment feasibility.

Table 1 Comparison of acceptability measures

Relative acceptability of ADHD treatment modalities

At the time of diagnosis, parentsCitation25,Citation29 and childrenCitation25 view psychosocial treatment as a more acceptable option than medication. One study found that ADHD knowledge at the time of diagnosis was positively correlated with acceptability of psychosocial treatment but not medication.Citation31 Another study found that medication acceptability at the time of diagnosis was significantly higher among Caucasian parents compared with non-Caucasian parents (25% of sample).Citation29 Actual experience with medication can increase parent-reported acceptability of medication treatment for ADHD.Citation25,Citation27 Interestingly, increased acceptability of medication after the initial medication trial was related to increased parent knowledge of ADHD and ADHD treatment modalitiesCitation25 and not to the degree of child symptom reduction.Citation25,Citation27 With experience, some parents may come to find combination treatment most acceptable.Citation25,Citation26

Acceptability of psychosocial treatments among experienced parents

Among parents with past experience with psychosocial treatments, views of effectiveness were positively correlated with acceptability of psychosocial treatments in one studyCitation28 and were unrelated in another study.Citation32 One study found that psychosocial treatment acceptability (but not psychosocial treatment feasibility) was higher among mothers than among fathers.Citation32 The same study found that psychosocial treatment acceptability for both mothers and fathers was positively correlated with children’s externalizing problems.Citation32 Psychosocial treatment acceptability was also higher among mothers who knew an acquaintance with ADHD than among those who did not.Citation32 One study found that parent acceptability of psychosocial treatments decreased after participating for 12 months in either parent training or support groups.Citation31 It is not clear whether this was due to perceived lack of effectiveness or other factors. Another study found that ADHD knowledge among fathers was positively correlated with past participation in psychosocial treatments.Citation30

No study found psychosocial treatment acceptability to be related to initiation (attending at least one session) of recommended psychosocial treatmentCitation29,Citation31,Citation32 or the number of sessions attended.Citation32 It is noteworthy that there was limited variability in the high ratings of psychosocial treatment acceptability in two of the three studies that examined this relationship.Citation29,Citation31 One study found that ADHD knowledge predicted attending at least one parent training or support group.Citation31

Acceptability of medication treatments among experienced parents

Among parents with past experience with medication treatment, views of effectiveness were not related to medication acceptability in one studyCitation28 but were positively correlated with medication acceptability among mothers (but not fathers) in another study.Citation32 Among mothers, ADHD knowledge was negatively correlated with medication acceptability in one studyCitation30 but positively correlated with medication acceptability for both mothers and fathers in another study.Citation32 One study found no significant difference between mothers and fathers on medication acceptability.Citation32 Side effect ratings were negatively correlated with medication acceptability among mothers but not fathers.Citation32

Research on the relationship between acceptability and medication adherence has mixed findings. One study found that medication acceptability and ADHD knowledge predicted implementing the recommendation to initiate a trial of medication (eg, taking at least one methylphenidate or placebo pill),Citation31 but another study found no such relationship.Citation32 Krain et alCitation29 found that significantly more Caucasian children than non-Caucasian children (79% vs 27%) initiated medication (eg, ingestion of at least one pill) during the follow-up period (eg, average 3.7 months). After controlling for race, acceptability ratings significantly predicted initiation of medication.Citation29 Johnston and FineCitation27 reported that following a medication titration, medication adherence (ie, composite score comprising missed pills; missed appointments; saliva methylphenidate; and parent-, teacher-, and physician-reported compliance) over 3 months of treatment was not related to acceptability scores (either before or after the initial trial of medication), consumer satisfaction, treatment response, or recommended dosage. Likewise, Corkum et alCitation31 found no relationship between acceptability and adherence. In this study, the adherent category was defined by taking ≥50% of pills based on pill count. Based on this definition, 36/68 (53%) adhered to treatment, with those randomized to medication being more adherent than those randomized to placebo (25/35 = 74% vs 11/34 = 32%). By 12 months, parent knowledge of ADHD increased significantly, but ADHD knowledge was not related to adherence.

Limitations of acceptability research

Acceptability research among parents of children with ADHD has several limitations. First, studies employ different measures of acceptability and include samples that vary considerably with regard to their past experience with ADHD treatment modalities. These factors make it challenging to interpret contradictory findings across studies. Second, only two of the eight studies reviewed assessed the relative acceptability of combined treatment (eg, both psychosocial and medication treatment).Citation25,Citation26 This appears to be an important distinction, as combined treatment may be viewed more favorably than either treatment in isolation.Citation26 Third, the child’s perspective on acceptability is almost completely neglected. Only one study collected these responses from children at diagnosis,Citation25 and no attempt was made to ascertain whether the child’s view of acceptability changed after trying treatment. Likewise, few studies examined how the views of fathersCitation30,Citation32 and minoritiesCitation29 might differ. Fourth, there are few longitudinal studies that assess change in acceptability over time,Citation25,Citation27,Citation31 and these studies are limited by attrition (eg, only 27/50 completed follow-up, with those initiating medication more likely to complete surveys)Citation25 and selection bias (eg, sample included only those willing to try medicationCitation27 or willing to be randomized to a 12-month treatment trial).Citation31 Finally, analyses related to prediction of medication adherence may be confounded by the inclusion of children receiving a placebo.Citation31 Adherence was extremely poor in the placebo group and may reflect discontinuation due to lack of effectiveness.Citation31

Summary of acceptability studies

It seems clear that psychosocial treatments are generally more acceptable to parents than medication initially and that acceptability can change over time as parents garner valuable experience of managing ADHD with a variety of treatment modalities. However, acceptability alone has not been shown to predict implementation of psychosocial treatment, which is likely influenced by a variety of factors, such as service availability and feasibility of family attendance (eg, time and affordability). Likewise, the relationship between acceptability and medication initiation appears inconsistent. Continuing medication after a titration trial is likely related to a variety of factors (ie, perceived need, perceived benefit, perceived side effects/concerns, patient acceptance, social support, and cost), of which acceptability is just one. Therefore, the construct of “acceptability” appears to have limited explanatory value in understanding child and caregiver ADHD treatment preferences. As such, we look to other bodies of literature for additional insights.

Qualitative and quantitative research assessing treatment preferences

Qualitative research methods are another way to better understand child and parent preferences about ADHD treatment. By allowing themes to emerge, rather than limiting inquiry to predefined constructs expected to explain a phenomenon, qualitative studies have enabled parents and children with ADHD to identify aspects of treatment that are important to them, using their own words. In addition, quantitative research that has built on these qualitative research studies has contributed important insights by exploring a variety of constructs identified by parents and children. This literature, which is reviewed below, spans the long and winding road traveled by families from the onset of child problem behaviors to entering the medical system, receiving a diagnosis, negotiating the initial treatment plan, and subsequently revisiting and revising the treatment plan. Collectively, this literature illustrates that treatment preferences are often dynamic, informed by real-world experience with a variety of ADHD treatments, and context dependent as family goals/priorities evolve and progress toward these target outcomes is appraised.

Parent treatment preferences

The initial decision to seek medical help for ADHD symptoms is influenced by a parent’s explanatory model of ADHD (eg, parental beliefs about etiology, expected time course, severity, parental worries, preferred treatments, and desired treatment outcomes). One study examined such beliefs among parents of children “at risk” for ADHD who subsequently met diagnostic criteria for ADHD based on parent reports on the Diagnostic Interview Schedule for Children Version IV.Citation33 In this study, parents of untreated children, compared with parents of children who had received psychosocial and/or medication treatment for ADHD in the past year, were less likely to 1) believe that ADHD would have a long time course, 2) voice concern about their child having a behavioral or emotional disturbance, and 3) state a goal related to improved child emotional functioning (eg, self-esteem and happiness).Citation33 Among parents of untreated children, two- thirds did not perceive a need for treatment, and 45% had negative expectations for treatment.Citation33 Another qualitative study identified four treatment trajectories among families: 1) delay to diagnosis, 2) initial nonmedication treatment pattern, 3) reluctant receipt of diagnosis, and 4) rapid engagement in medication treatment.Citation34 Treatment trajectories are influenced by parent explanatory models, extended networks (eg, family members, friends, religious leaders, school officials, and clinicians), and medical utilization factors.Citation34Citation36 Of note, families whose explanatory model closely parallel the biomedical model for ADHD (either from the time of diagnosis or after reframing) appear more likely to engage and maintain use of medication.Citation34,Citation35,Citation37 Parents in the initial nonmedication treatment pattern choose to start with “less or no harm approaches”.Citation34 Home care approaches utilized by parents range from those consistent with evidence-based psychosocial treatment principles to those based more on popular myths (eg, elimination of sugar from diet).Citation5Citation7,Citation38Citation40 Many parents of children with ADHD or at risk for ADHD believe that ADHD medications are overprescribed by doctors.Citation41Citation43 Some parents prefer behavior modification and are reluctant to initiate medication.Citation33,Citation35,Citation39,Citation42,Citation44 Despite this reluctance, many parents feel like they have exhausted parenting approaches and must resort to trying medication.Citation35,Citation36 Parents who seek treatment are often driven by their worries about the consequences of their child’s problems if left untreated.Citation35,Citation36,Citation39,Citation45 Inclusion of medication in the treatment plan is also facilitated by parent acceptance of the diagnosis of ADHDCitation34,Citation35 and recognition of their child’s functional impairments.Citation34,Citation35 Trying medication and/or contrasting time on and off medication helps parents to understand the effects and/or side effects for their child and informs subsequent decisions about continuing medication.Citation35,Citation36,Citation46,Citation47 A common barrier to trying a full range of dosages is family resistance to increasing the dosage after seeing improvement in their child’s behavior on the initial (eg, lowest) dose.Citation48 Parents tend to prefer medications that have a long duration.Citation49 Some parents come to view medication as necessary to controlling ADHD symptoms enough so that they can then achieve some limited success with psychosocial techniques.Citation50 Parents continue to experience fears and worries related to the potential for long-term side effects, even if their child shows marked improvement.Citation35,Citation36,Citation39,Citation45,Citation51 This phenomenon is especially pertinent given ongoing public discussion of the effect of stimulant medications on growthCitation52,Citation53 and the possible linkage between sudden cardiac death and the use of ADHD medications.Citation54Citation58

Cultural variations in parent treatment preferences

Parental beliefs about ADHD help explain cultural variations seen in disparities in the rate of medication initiation.Citation19,Citation59,Citation60 Understanding ADHD as a medical illnessCitation61Citation63 and accepting medication treatment is more common among well-educated, affluent, and Caucasian familiesCitation33,Citation41,Citation64 and among mothersCitation65 rather than fathers.Citation66,Citation67 Parents from less affluent or minority ethnic backgrounds may have underlying beliefs that contribute to lower rates of medication utilization for ADHD. Whether these beliefs constitute well-informed preferences is debatable. Qualitative studies have shed some light on these subcultural beliefs. Studies among Latino parents demonstrate a lack of trust and shared understanding about the child’s problemCitation34 and a preference for treatment options other than medication because they understand medication to be addictive, dulling of cognitive processes, and inappropriate for behavioral problems.Citation68,Citation69 African-American parents report 1) distrust of ADHD as a diagnosis and of physicians who are quick to prescribe medication, 2) concern that stimulants will lead to drug abuse later in life, and 3) lack of support for medical treatment from their social networks.Citation37,Citation43,Citation70Citation74 Lack of support from social networks is not surprising given the largely negative beliefs and attitudes held about the use of psychoactive medications in childrenCitation75 and the lower likelihood among minorities of espousing the belief that ADHD is a real disorder.Citation76

Child and adolescent treatment preferences

Child and adolescent treatment preferences are an understudied area. Studies have documented that 22%–50% of children dislike taking medication for ADHD.Citation67,Citation77,Citation78 In addition, 40%–65% of children avoid taking their medication.Citation42,Citation78 Common avoidance tactics include arguments with parents and/or refusal to take it, throwing it away if no one is watching, pretending to take medication and then throwing it away, or deliberately failing to remind a parent who forgot to give it.Citation78 Common reasons for avoidance include dislike of pills, embarrassment/social stigma, side effects, negative effect on self-esteem, interference with activities (eg, sports performance), and concern about addiction.Citation42,Citation44,Citation78,Citation79 Children in these studies also reported a lack of perceived need for medication, which may relate to the consistent finding that children with ADHD have unrealistically high self- belief about their skills and competence.Citation80Citation85 In addition, many children do not perceive any benefit from taking medication.Citation44,Citation67,Citation78,Citation86 Child and parent appraisal of medication effectiveness disagrees in 25%–33% of cases.Citation87 Twelve percent of children report that they would discontinue treatment if given the choice.Citation67,Citation77 Given the pervasive nature of child dislike and avoidance of medication, it is not surprising that oppositional symptoms have been associated with poor treatment adherence,Citation88 and parents have endorsed child reluctance to take their medication as a major reason for discontinuing treatment.Citation36,Citation42,Citation89 Beyond avoiding medication, some children simply forget to take their medication.Citation90,Citation91

Treatment preferences change over time

In early work conducted by Firestone, the major reasons parents gave for stopping medication were that they were not comfortable with the idea of medicating their children or that their children were reluctant to take their medication.Citation89 Following the initial titration, side effects, when present, were not cited by parents as an important factor in their decision to discontinue treatment.Citation89 In 2005, 16 parents of children with ADHD who had stopped taking medication were asked open-ended questions about the reasons for discontinuation.Citation92 The most common reasons offered were side effect experiences (n = 6), summer medication break (n = 3), and trying to keep the child off medication to see whether ADHD would remit (n = 2). Three qualitative studies further depict parent decision making for their child with ADHD.Citation35,Citation36,Citation45 Parents described medication decisions as a complex balancing act, with concerns about past and present experiences of adverse effects weighed against the functional improvements seen at home and at school. In addition, parents also considered an uncertain and unpredictable future, with concerns about possible long-term risks of medication weighed against their goals and expectations for their child’s future. In addition, this dilemma does not end after a decision has been made and acted on. Rather, parents continually justified and re-evaluated decisions long after they had been made.

Limitations of qualitative and quantitative research assessing treatment preferences

Qualitative studies are limited by small, geographically confined samples. Results from these qualitative studies cannot be generalized to all children with ADHD or their parents. However, qualitative research provides important insights into poorly understood phenomena that can subsequently be studied using quantitative methods to better characterize the prevalence of the phenomena and/or test implied hypotheses.Citation93 The research conducted by Bussing et alCitation92 represents the only prospective longitudinal study, leaving the majority of studies based on cross-sectional data. Both qualitative and quantitative studies reviewed are limited by a greater focus on medication rather than psychosocial treatments. There are plausible explanations for this. First, medication has long been a more controversial and polarizing topic among parents and the media than psychosocial treatment. As such, it has been a popular topic for research. In addition, medication is widely available, so the decision of whether or not to try medication is faced by nearly every parent of a child diagnosed with ADHD. In contrast, psychosocial treatments, although highly acceptable to parents, vary in availability, cost, and quality. As a result, utilization of psychosocial treatments may be less about parent preference and more about barriers to access in a resource-constrained environment. Moreover, there are more datasets (eg, Medicaid) available to investigate utilization of medication than psychosocial treatments. Unfortunately, the current ADHD treatment preference literature does not adequately account for availability of services when assessing preferences. It is possible that parent preferences might change if evidence-based psychosocial treatments were readily available. It may be that parents might show more preference for psychosocial treatment with greater availability. It is also possible that parents might show less preference with greater availability due to trying psychosocial treatments and finding that they did not fully address impairments.

Summary of qualitative and quantitative research assessing treatment preferences

After a child is diagnosed with ADHD, a variety of factors influence the initial selection of treatment modalities that are utilized. Initial parent and child preferences are shaped by their beliefs about the nature of the child’s problems and by information (and misinformation) received from a variety of sources, including social networks, the media, and health care providers. Subsequently, preferences become further informed by personal experience with various treatment modalities. Over time, treatment plans are revisited and revised (ie, treatment modalities are added and subtracted, and/or current approaches are modified) as families work with their health care team to establish a treatment plan that helps their child achieve goals while minimizing harms and costs. This process of optimizing care is similar to the family/self-management processes described for other chronic conditions.Citation94 Even when treatment plans are congruent with well-informed patient/parent preferences and values, there can be barriers to implementation and/or persistence with treatment. Children can forget to take medication, and parents might forget to give medication. Families can struggle with the out-of-pocket costs for medication and/or psychosocial treatments. Access to high-quality psychosocial treatments may be limited. When available, there are additional barriers to learning and implementing psychosocial treatment strategies.

Discussion

There are multiple treatments for ADHD that are effective. Because the treatment options differ on benefits and risks/costs, the best choice is preference sensitive and depends on how an informed patient/parent values the tradeoffs between options.Citation23 There are many publications examining variation in treatment utilization among children with ADHD. Most have focused on medication, as this is the most widely available treatment modality, and there are multiple sources of data available for analysis. However, these datasets are devoid of information about patient/parent preferences and knowledge regarding the likelihood of treatment outcomes (eg, benefits and risks/costs). Therefore, studies have not been able to distinguish between “unwarranted” and “warranted” sources of variation. For example, the nearly two-fold variation in medication use between children diagnosed with ADHD in Nebraska and CaliforniaCitation19 would be unwarranted if not consistent with the distribution of informed patient/parent treatment preferences.Citation23 Studies are needed to better characterize the amount of unwarranted variation in ADHD treatment patterns. Certainly, strategies are needed to ensure that 1) patients/parents are well informed about likely benefits and risks/costs of treatment and 2) patient/parent goals, preferences, and values are elicited and discussed. Shared decision making is one process to accomplish these objectives. Using shared decision-making tools, practitioners communicate information on the options, outcomes, probabilities, and scientific uncertainties, and patients/parents communicate the personal value they place on the benefits versus harms so that agreement on the best strategy can be reached.Citation95 Studies are needed to test shared decision-making interventions among parents of children with ADHD. In addition, studies are needed to determine the extent to which psychosocial treatments are excluded from the treatment plan due to family preference rather than poor access to services or physicians underestimating parent preferences for this modality.

As a chronic condition, it is natural for patient/parent goals, preferences, and values to evolve over time. Treatment plans must be revised to reflect these changes and progress made toward goals. It is not clear how often patient/parents and physicians explicitly set and/or revise goals for treatment, although there is some evidence that goals are infrequently documented in the medical record.Citation96,Citation97 In addition, it is not clear whether goals set are specific, measurable, attainable, relevant, and time bound. These dimensions are important in increasing the chance that goal setting leads to improvement. Citation98 Likewise, it is not clear how often patient/parent preferences and values are elicited and discussed. In one study, only 44% of parents of a child with psychosocial problems reported that their child’s doctor always asked about his/her ideas and opinions when planning care for their child.Citation99 Measuring meaningful outcomes over time is essential in order to help appraise progress toward goals.Citation3 The American Academy of Pediatrics recommends a wide range of methods to obtain information about progress on target symptoms, including office interviews, telephone conversations, teacher narratives, periodic behavior report cards, and behavioral ratings.Citation3 The behavioral ratings commonly collected in practice (eg, Connors and Vanderbilt Rating Scales) focus on symptoms and impairment. Tracking symptoms may be a good proxy for other functional outcomes given the strong negative correlation observed between ADHD symptoms and health-related quality of life (ie, lower symptoms related to better quality of life).Citation100Citation105 However, there is evidence that impairment often persists despite a reduction in ADHD symptoms.Citation106 Therefore, collection of impairment and potentially other measures may add value as adaptive functioning outcomes appear important to patients/parents.Citation107,Citation108 There is a significant dropoff in the number of parent and teacher behavioral ratings that are obtained by physicians over time.Citation106 It is not clear to what extent this phenomenon is based on 1) a conscious decision to discontinue monitoring based on child symptom remission documented on a previous checklist or 2) challenges for parents and physicians to sustain engagement in ongoing monitoring activities in the absence of an ADHD-precipitated child/family crisis. Regardless, the absence of such data makes it difficult to understand the changes in treatment utilization that occur over time. In the absence of symptom remission and/or goal attainment, what factors contribute to treatment discontinuation? Investigators from the MTA recently identified the need to address this gap in the literature as they stated: “It is clear that additional studies are needed to characterize who starts and who stops treatment with medication, and for what reasons, during the course of long-term treatment”.Citation109

Conclusions

Treatment planning for children with ADHD is a dynamic process. Ideally, this process includes consideration of scientific evidence about the efficacy of treatments as well as patient/parent goals, preferences, and values. There are challenges to ensure that patient/parent preferences are consistently well informed, elicited, and discussed in the treatment planning process. Interventions are needed to promote such interactions. Such research is a necessary step that will enable more meaningful conclusions to be drawn about the appropriateness of treatment utilization rates in a given population.

Acknowledgments

The authors are supported by Award Numbers K23MH083027 (Dr Brinkman) and K24MH064478 (Dr Epstein) from the National Institute of Mental Health. Dr Epstein also receives grant funding from Eli Lilly and Company. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute of Mental Health or the National Institutes of Health.

Disclosure

The authors report no conflicts of interest in this work.

References

  • FroehlichTELanphearBPEpsteinJNBarbaresiWJKatusicSKKahnRSPrevalence, recognition, and treatment of attention-deficit/hyperactivity disorder in a national sample of US childrenArch Pediatr Adolesc Med2007161985786417768285
  • The MTA Cooperative GroupA 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorderArch Gen Psychiatry199956121073108610591283
  • American Academy of PediatricsSubcommittee on Attention-Deficit/ Hyperactivity Disorder and Committee on Quality Improvement. Clinical practice guideline: treatment of the school-aged child with attention-deficit/ hyperactivity disorderPediatrics200110841033104411581465
  • PliszkaSAACAP Work Group on Quality Issues. Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorderJ Am Acad Child Adolesc Psychiatry200746789492117581453
  • ChanERappaportLAKemperKJComplementary and alternative therapies in childhood attention and hyperactivity problemsJ Dev Behav Pediatr20032414812584479
  • JohnstonCSeippCHommersenPHozaBFineSTreatment choices and experiences in attention deficit and hyperactivity disorder: relations to parents’ beliefs and attributionsChild Care Health Dev200531666967716207224
  • ConcannonPETangYPManagement of attention deficit hyperactivity disorder: a parental perspectiveJ Paediatr Child Health2005411262563016398864
  • RucklidgeJJJohnstoneJKaplanBJNutrient supplementation approaches in the treatment of ADHDExpert Rev Neurother20099446147619344299
  • SwansonJMKraemerHCHinshawSPClinical relevance of the primary findings of the MTA: success rates based on severity of ADHD and ODD symptoms at the end of treatmentJ Am Acad Child Adolesc Psychiatry200140216817911211365
  • PelhamWEJrFabianoGAEvidence-based psychosocial treatments for attention-deficit/hyperactivity disorderJ Clin Child Adolesc Psychol200837118421418444058
  • BarkleyRASheltonTLCrosswaitCMulti-method psycho-educational intervention for preschool children with disruptive behavior: preliminary results at post-treatmentJ Child Psychol Psychiatry200041331933210784079
  • BussingRZimaBTBelinTRVariations in ADHD treatment among special education studentsJ Am Acad Child Adolesc Psychiatry19983799689769735616
  • The MTA Cooperative GroupModerators and mediators of treatment response for children with attention-deficit/hyperactivity disorder: the Multimodal Treatment Study of children with attention-deficit/hyperactivity disorderArch Gen Psychiatry199956121088109610591284
  • GreenhillLLSwansonJMVitielloBImpairment and deportment responses to different methylphenidate doses in children with ADHD: the MTA titration trialJ Am Acad Child Adolesc Psychiatry200140218018711211366
  • VitielloBSevereJBGreenhillLLMethylphenidate dosage for children with ADHD over time under controlled conditions: lessons from the MTAJ Am Acad Child Adolesc Psychiatry200140288196
  • EpsteinJNRabinerDJohnsonDEImproving attention-deficit/hyperactivity disorder treatment outcomes through use of a collaborative consultation treatment service by community-based pediatricians: a cluster randomized trialArch Pediatr Adolesc Med2007161983584017768282
  • PappadopulosEJensenPSChaitARMedication adherence in the MTA: saliva methylphenidate samples versus parent report and mediating effect of concomitant behavioral treatmentJ Am Acad Child Adolesc Psychiatry200948550151019307987
  • HudsonJLMillerGEKirbyJBExplaining racial and ethnic differences in children’s use of stimulant medicationsMed Care200745111068107518049347
  • Centers for Disease Control and Prevention (CDC)Mental health in the United States. Prevalence of diagnosis and medication treatment for attention-deficit/hyperactivity disorder – United States, 2003MMWR Morb Mortal Wkly Rep2005543484284716138075
  • MarcusSCWanGJKemnerJEOlfsonMContinuity of methylphenidate treatment for attention-deficit/hyperactivity disorderArch Pediatr Adolesc Med2005159657257815939858
  • SanchezRJCrismonMLBarnerJCBettingerTWilsonJPAssessment of adherence measures with different stimulants among children and adolescentsPharmacotherapy200525790991716006269
  • BokhariFASHeilandFLevinePRayGTRisk factors for discontinuing drug therapy among children with ADHDHealth Serv Outcomes Res Methodol200883134158
  • WennbergJEFisherESSkinnerJSGeography and the debate over Medicare reformHealth Aff (Millwood)2002Suppl Web ExclusivesW9611412703563
  • KazdinAEAcceptability of alternative treatments for deviant child behaviorJ Appl Behav Anal19801322592737380752
  • LiuCRobinALBrennerSEastmanJSocial acceptability of methylphenidate and behavior modification for treating attention deficit hyperactivity disorderPediatrics19918835605651881737
  • GageJDWilsonLJAcceptability of attention-deficit/hyperactivity disorder interventions: a comparison of parentsJ Atten Disord200043174182
  • JohnstonCFineSMethods of evaluating methylphenidate in children with attention deficit hyperactivity disorder: acceptability, satisfaction, and complianceJ Pediatr Psychol19931867177308138866
  • JohnstonCHommersenPSeippCAcceptability of behavioral and pharmacological treatments for attention-deficit/hyperactivity disorder: relations to child and parent characteristicsBehav Ther2008391223218328867
  • KrainALKendallPCPowerTJThe role of treatment acceptability in the initiation of treatment for ADHDJ Atten Disord20059242543416371665
  • RostainALPowerTJAtkinsMSAssessing parents’ willingness to pursue treatment for children with attention-deficit hyperactivity disorderJ Am Acad Child Adolesc Psychiatry19933211751818428869
  • CorkumPRimerPSchacharRParental knowledge of attention- deficit hyperactivity disorder and opinions of treatment options: impact on enrollment and adherence to a 12-month treatment trialCan J Psychiatry199944101043104810637684
  • BennettDSPowerTJRostainALCarrDEParent acceptability and feasibility of ADHD interventions: assessment, correlates, and predictive validityJ Pediatr Psychol19962156436578936894
  • BussingRGaryFAMillsTLGarvanCWParental explanatory models of ADHD: gender and cultural variationsSoc Psychiatry Psychiatr Epidemiol2003381056357514564385
  • LeslieLKPlemmonsDMonnARPalinkasLAInvestigating ADHD treatment trajectories: listening to families’ stories about medication useJ Dev Behav Pediatr200728317918817565284
  • BrinkmanWBShermanSNZmitrovichARParental angst making and revisiting decisions about treatment of attention-deficit/hyperactivity disorderPediatrics2009124258058919651580
  • CharachASkybaACookLAntleBJUsing stimulant medication for children with ADHD: what do parents say? A brief reportJ Can Acad Child Adolesc Psychiatry2006152758318392197
  • DosReisSMychailyszynMPEvans-LackoSEBeltranARileyAWMyersMAThe meaning of attention-deficit/hyperactivity disorder medication and parents’ initiation and continuity of treatment for their childJ Child Adolesc Psychopharmacol200919437738319702489
  • WolraichMLWilsonDBWhiteJWThe effect of sugar on behavior or cognition in children. A meta-analysisJAMA199527420161716217474248
  • BussingRGaryFAPractice guidelines and parental ADHD treatment evaluations: friends or foes?Harv Rev Psychiatry20019522323311553526
  • BussingRZimaBTGaryFAGarvanCWUse of complementary and alternative medicine for symptoms of attention-deficit hyperactivity disorderPsychiatr Serv20025391096110212221307
  • BussingRSchoenbergNEPerwienARKnowledge and information about ADHD: evidence of cultural differences among African-American and white parentsSoc Sci Med19984679199289541077
  • DosReisSZitoJMSaferDJSoekenKLMitchellJWJrEllwoodLCParental perceptions and satisfaction with stimulant medication for attention-deficit hyperactivity disorderJ Dev Behav Pediatr200324315516212806227
  • DosReisSButzALipkinPHAnixtJSWeinerCLChernoffRAttitudes about stimulant medication for attention-deficit/hyperactivity disorder among African American families in an inner city communityJ Behav Health Serv Res200633442343017078011
  • HenkerBWhalenCKThe many messages of medication: hyperactive children’s perceptions and attributionsSalzingerSAntrobusJGlickJThe Ecosystem of the “Sick” ChildNew York (NY)Academic Press Inc1980
  • HansenDLHansenEHCaught in a balancing act: parents’ dilemmas regarding their ADHD child’s treatment with stimulant medicationQual Health Res20061691267128517038757
  • NiklesCJClavarinoAMDel MarCBUsing n-of-1 trials as a clinical tool to improve prescribingBr J Gen Pract20055551217518015808031
  • KentMACamfieldCSCamfieldPRDouble-blind methylphenidate trials: practical, useful, and highly endorsed by familiesArch Pediatr Adolesc Med1999153121292129610591309
  • PliszkaSRLopezMCrismonMLA feasibility study of the children’s medication algorithm project (CMAP) algorithm for the treatment of ADHDJ Am Acad Child Adolesc Psychiatry200342327928712595780
  • MühlbacherACRudolphILinckeHJNüblingMPreferences for treatment of attention-deficit/hyperactivity disorder (ADHD): a discrete choice experimentBMC Health Serv Res2009914919678946
  • BullCWhelanTParental schemata in the management of children with attention deficit-hyperactivity disorderQual Health Res200616566467816611971
  • BergerIDorTNevoYGoldzweigGAttitudes toward attention- deficit hyperactivity disorder (ADHD) treatment: parents’ and children’s perspectivesJ Child Neurol20082391036104218487521
  • The MTA Cooperative GroupNational Institute of Mental Health Multimodal Treatment Study of ADHD follow-up: changes in effectiveness and growth after the end of treatmentPediatrics2004113476276915060225
  • SwansonJMHinshawSPArnoldLESecondary evaluations of MTA 36-month outcomes: propensity score and growth mixture model analysesJ Am Acad Child Adolesc Psychiatry20074681003101417667479
  • NissenSEADHD drugs and cardiovascular riskN Engl J Med2006354141445144816549404
  • PerrinJMFriedmanRAKnilansTKBlack Box Working GroupCardiovascular monitoring and stimulant drugs for attention-deficit/hyperactivity disorderPediatrics2008122245145318676566
  • VetterVLEliaJEricksonCCardiovascular monitoring of children and adolescents with heart disease receiving medications for attention deficit/hyperactivity disorder [corrected]: a scientific statement from the American Heart Association Council on Cardiovascular Disease in the Young Congenital Cardiac Defects Committee and the Council on Cardiovascular NursingCirculation2008117182407242318427125
  • WilensTEPrinceJBSpencerTJBiedermanJStimulants and sudden death: what is a physician to do?Pediatrics200611831215121916951018
  • BiedermanJSpencerTJWilensTEPrinceJBFaraoneSVTreatment of ADHD with stimulant medications: response to Nissen perspective in the New England Journal of MedicineJ Am Acad Child Adolesc Psychiatry200645101147115016840880
  • OlfsonMGameroffMJMarcusSCJensenPSNational trends in the treatment of attention deficit hyperactivity disorderAm J Psychiatry200316061071107712777264
  • StevensJHarmanJSKelleherKJRace/ethnicity and insurance status as factors associated with ADHD treatment patternsJ Child Adolesc Psychopharmacol2005151896
  • HarborneAWolpertMClareLMaking sense of ADHD: a battle for understanding? Parents’ views of their children being diagnosed with ADHDClin Child Psychol Psychiatry200493327339
  • KlasenHA name, what’s in a name? The medicalization of hyperactivity, revisitedHarv Rev Psychiatry20007633434410749390
  • MalacridaCMedicalization, ambivalence and social control: mothers’ descriptions of educators and ADD/ADHDHealth (London)200481618015018718
  • BussingRZimaBTBelinTRDifferential access to care for children with ADHD in special education programsPsychiatr Serv1998499122612299735968
  • SinghIDoing their jobs: mothering with Ritalin in a culture of mother-blameSoc Sci Med20045961931205
  • SinghIBoys will be boys: fathers’ perspectives on ADHD symptoms, diagnosis, and drug treatmentHarv Rev Psychiatry200311630831614713567
  • BaxleyGBTurnerPFGreenwoldWEHyperactive children’s knowledge and attitudes concerning drug treatmentJ Pediatr Psychol197834172176
  • ArciaEFernándezMCJáquezMLatina mothers’ stances on stimulant medication: complexity, conflict, and compromiseJ Dev Behav Pediatr200425531131715502547
  • PerryCEHattonDKendallJLatino parents’ accounts of attention deficit hyperactivity disorderJ Transcult Nurs200516431232116160193
  • DosReisSMychailyszynMPMyersMRileyAWComing to terms with ADHD: how urban African-American families come to seek care for their childrenPsychiatr Serv200758563664117463344
  • OlaniyanOdosReisSGarriettVCommunity perspectives of childhood behavioral problems and ADHD among African American parentsAmbul Pediatr20077322623117512883
  • GuevaraJPFeudtnerCRomerDFragmented care for inner-city minority children with attention-deficit/hyperactivity disorderPediatrics20051164e512e51716199679
  • DavidsonJCFordDYPerceptions of attention deficit hyperactivity disorder in one African American communityJ Negro Educ2001704264274
  • DosReisSBarksdaleCLShermanAMaloneyKCharachAStigmatizing experiences of parents of children with a new diagnosis of ADHDPsychiatr Serv201061881181620675840
  • PescosolidoBAPerryBLMartinJKMcLeodJDJensenPSStigmatizing attitudes and beliefs about treatment and psychiatric medications for children with mental illnessPsychiatr Serv200758561361817463340
  • McLeodJDFettesDLJensenPSPescosolidoBAMartinJKPublic knowledge, beliefs, and treatment preferences concerning attention-deficit hyperactivity disorderPsychiatr Serv200758562663117463342
  • BowenJFentonTRappaportLStimulant medication and attention deficit-hyperactivity disorder. The child’s perspectiveAm J Dis Child199114532912952003477
  • SleatorEKUllmannRKvon NeumannAHow do hyperactive children feel about taking stimulants and will they tell the doctor?Clin Pediatr (Phila)19822184744796123398
  • KendallJHattonDBeckettALeoMChildren’s accounts of attention-deficit/hyperactivity disorderANS Adv Nurs Sci200326211413012795540
  • HozaBGerdesACHinshawSPSelf-perceptions of competence in children with ADHD and comparison childrenJ Consult Clin Psychol200472338239115279522
  • HozaBOwensJSPelhamWEParent cognitions as predictors of child treatment response in attention-deficit/hyperactivity disorderJ Abnorm Child Psychol200028656958311104318
  • HozaBPelhamWEJrDobbsJOwensJSPillowDRDo boys with attention-deficit/hyperactivity disorder have positive illusory self- concepts?J Abnorm Psychol2002111226827812004833
  • HozaBPelhamWEMilichRPillowDMcBrideKThe self-perceptions and attributions of attention deficit hyperactivity disordered and nonreferred boysJ Abnorm Child Psychol19932132712868335764
  • OwensJSGoldfineMEEvangelistaNMHozaBKaiserNMA critical review of self-perceptions and the positive illusory bias in children with ADHDClin Child Fam Psychol Rev200710433535117902055
  • OwensJSHozaBThe role of inattention and hyperactivity/impulsivity in the positive illusory biasJ Consult Clin Psychol200371468069112924673
  • PelhamWEHozaBPillowDREffects of methylphenidate and expectancy on children with ADHD: behavior, academic performance, and attributions in a summer treatment program and regular classroom settingsJ Consult Clin Psychol200270232033511952190
  • EfronDJarmanFCBarkerMJChild and parent perceptions of stimulant medication treatment in attention deficit hyperactivity disorderJ Paediatr Child Health19983432882929633980
  • ThiruchelvamDCharachASchacharRJModerators and mediators of long-term adherence to stimulant treatment in children with ADHDJ Am Acad Child Adolesc Psychiatry200140892292811501692
  • FirestonePFactors associated with children’s adherence to stimulant medicationAm J Orthopsychiatry19825234474577114173
  • MeauxJBHesterCSmithBShoptawAStimulant medications: a trade-off? The lived experience of adolescents with ADHDJ Spec Pediatr Nurs200611421422616999743
  • KnippDKTeens’ perceptions about attention deficit/hyperactivity disorder and medicationsJ Sch Nurs200622212012516563036
  • BussingRZimaBTMasonDHouWGarvanCWFornessSUse and persistence of pharmacotherapy for elementary school students with attention-deficit/hyperactivity disorderJ Child Adolesc Psychopharmacol2005151788715741789
  • GiacominiMKCookDJUsers’ guides to the medical literature: XXIII. Qualitative research in health care A. Are the results of the study valid? Evidence-Based Medicine Working GroupJAMA2000284335736210891968
  • WagnerEHAustinBTvon KorffMOrganizing care for patients with chronic illnessMilbank Q19967445115448941260
  • O’ConnorAMLlewellyn-ThomasHAFloodABModifying unwarranted variations in health care: shared decision making using patient decision aidsHealth Aff (Millwood)2004Suppl Web ExclusivesVAR6372
  • EpsteinJNLangbergJMLichtensteinPKMainwaringBALuzaderCPStarkLJCommunity-wide intervention to improve the attention-deficit/hyperactivity disorder assessment and treatment practices of community physiciansPediatrics20081221192718595982
  • HomerCJHorvitzLHeinrichPForbesPLesneskiCPhillipsJImproving care for children with attention deficit hyperactivity disorder: assessing the impact of self-assessment and targeted training on practice performanceAmbul Pediatr20044543644115369417
  • DoranGTThere’s a S.M.A.R.T. way to write management’s goals and objectivesManage Rev198170113536
  • HartCNKelleherKJDrotarDScholleSHParent-provider communication and parental satisfaction with care of children with psychosocial problemsPatient Educ Couns200768217918517643912
  • KlassenAFMillerAFineSHealth-related quality of life in children and adolescents who have a diagnosis of attention-deficit/hyperactivity disorderPediatrics20041145e541e54715520087
  • PerwienARFariesDEKratochvilCJSumnerCRKelseyDKAllenAJImprovement in health-related quality of life in children with ADHD: an analysis of placebo controlled studies of atomoxetineJ Dev Behav Pediatr200425426427115308927
  • PerwienARKratochvilCJFariesDEVaughanBSSpencerTBrownRTAtomoxetine treatment in children and adolescents with attention-deficit hyperactivity disorder: what are the long-term health-related quality-of-life outcomes?J Child Adolesc Psychopharmacol200616671372417201615
  • RentzAMMatzaLSSecnikKSwensenARevickiDAPsychometric validation of the child health questionnaire (CHQ) in a sample of children and adolescents with attention-deficit/hyperactivity disorderQual Life Res200514371973416022065
  • SawyerMGWhaitesLReyJMHazellPLGraetzBWBaghurstPHealth-related quality of life of children and adolescents with mental disordersJ Am Acad Child Adolesc Psychiatry200241553053712014785
  • VarniJWBurwinkleTMThe PedsQL as a patient-reported outcome in children and adolescents with attention-deficit/hyperactivity disorder: a population-based studyHealth Qual Life Outcomes200642616630344
  • EpsteinJNLangbergJMLichtensteinPKAttention-deficit/hyperactivity disorder outcomes for children treated in community-based pediatric settingsArch Pediatr Adolesc Med2010164216016520124145
  • SaylorKEBuermeyerCMSpencerTJBarkleyRAAdaptive changes related to medication treatment of ADHD: listening to parents of children in clinical trials of a novel nonstimulant medicationJ Clin Psychiatry200263Suppl 12232812562058
  • CunninghamCEA family-centered approach to planning and measuring the outcome of interventions for children with attention-deficit/hyperactivity disorderAmbul Pediatr200771 Suppl607217261485
  • SwansonJArnoldLEKraemerHEvidence, interpretation, and qualification from multiple reports of long-term outcomes in the Multimodal Treatment Study of children with ADHD (MTA): Part II: supporting detailsJ Atten Disord2008121154318573924